{"id":40083,"date":"2025-08-26T14:20:16","date_gmt":"2025-08-26T06:20:16","guid":{"rendered":"https:\/\/flcube.com\/?p=40083"},"modified":"2025-08-26T14:20:17","modified_gmt":"2025-08-26T06:20:17","slug":"hengrui-pharmaceuticals-secures-nmpa-approval-for-hrs%e2%80%912162-and-hrs%e2%80%916093-clinical-trials","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=40083","title":{"rendered":"Hengrui Pharmaceuticals Secures NMPA Approval for HRS\u20112162 and HRS\u20116093 Clinical Trials"},"content":{"rendered":"\n<p>China\u2011based Jiangsu Hengrui Pharmaceuticals Co., Ltd. (<a href=\"https:\/\/www.google.com\/finance\/quote\/1276:HKG\">HKG: 1276<\/a>, <a href=\"https:\/\/www.google.com\/finance\/quote\/600276:SHA\">SHA: 600276<\/a>) announced that its two investigational agents\u2014<strong>HRS\u20112162<\/strong> and <strong>HRS\u20116093<\/strong>\u2014have received clearance from the National Medical Products Administration (NMPA) to enter clinical testing. The approval marks a significant step forward for the company\u2019s pipeline and positions Hengrui as a pioneer in two distinct therapeutic areas.<\/p>\n\n\n\n<p><strong>HRS\u20112162: A Next\u2011Generation Muscle\u2011Relaxant Antagonist<\/strong><\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Mechanism<\/strong>: Designed to reverse the effects of neuromuscular blocking agents (NMBAs) such as rocuronium and cisatracurium, restoring muscle tone rapidly and safely.<\/li>\n\n\n\n<li><strong>Clinical Trial Focus<\/strong>: The study will evaluate efficacy and safety in patients undergoing procedures that require reversible muscle relaxation.<\/li>\n\n\n\n<li><strong>Market Gap<\/strong>: No comparable product has received regulatory approval in China or abroad, giving Hengrui a first\u2011to\u2011market advantage in this niche.<\/li>\n<\/ul>\n\n\n\n<p><strong>HRS\u20116093: Targeted Oral Inhibitor of KRAS G12D<\/strong><\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Target<\/strong>: Selective binding to the KRAS G12D mutant protein, a driver mutation found in a subset of solid tumors.<\/li>\n\n\n\n<li><strong>Therapeutic Potential<\/strong>: Early pre\u2011clinical data suggest potent anti\u2011tumor activity with a favorable safety profile.<\/li>\n\n\n\n<li><strong>Trial Design<\/strong>: Monotherapy study in patients with KRAS G12D\u2011positive solid tumors, aiming to establish proof of concept and dose\u2011response relationships.<\/li>\n<\/ul>\n\n\n\n<p><strong>Strategic Implications for Hengrui<\/strong><\/p>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Aspect<\/th><th>Impact<\/th><\/tr><\/thead><tbody><tr><td><strong>Pipeline Diversification<\/strong><\/td><td>Adds two first\u2011in\u2011class agents across anesthesia support and oncology.<\/td><\/tr><tr><td><strong>Regulatory Momentum<\/strong><\/td><td>NMPA approval accelerates the drug development timeline and reduces regulatory uncertainty.<\/td><\/tr><tr><td><strong>Commercial Opportunity<\/strong><\/td><td>Potential to capture high\u2011value markets in peri\u2011operative care and precision oncology.<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<p><strong>Looking Ahead<\/strong><br>With the NMPA clearance in place, Hengrui Pharmaceuticals can now focus on accelerating the clinical development of HRS\u20112162 and HRS\u20116093, while leveraging its established manufacturing and commercialization capabilities. The success of these trials could open doors to global partnerships, expand investor interest, and reinforce Hengrui\u2019s reputation as an innovator in the Chinese pharmaceutical landscape.<a href=\"https:\/\/flcube.com\/\">-Fineline Info &amp; Tech<\/a><\/p>\n\n\n\n<div data-wp-interactive=\"core\/file\" class=\"wp-block-file\"><object data-wp-bind--hidden=\"!state.hasPdfPreview\" hidden class=\"wp-block-file__embed\" data=\"https:\/\/flcube.com\/wp-content\/uploads\/2025\/08\/600276_20250826_C1ZK.pdf\" type=\"application\/pdf\" style=\"width:100%;height:600px\" aria-label=\"Embed of 600276_20250826_C1ZK.\"><\/object><a id=\"wp-block-file--media-206ebd0a-e70f-40bb-9ea3-324b0e9958a6\" href=\"https:\/\/flcube.com\/wp-content\/uploads\/2025\/08\/600276_20250826_C1ZK.pdf\">600276_20250826_C1ZK<\/a><a href=\"https:\/\/flcube.com\/wp-content\/uploads\/2025\/08\/600276_20250826_C1ZK.pdf\" class=\"wp-block-file__button wp-element-button\" download aria-describedby=\"wp-block-file--media-206ebd0a-e70f-40bb-9ea3-324b0e9958a6\">Download<\/a><\/div>\n","protected":false},"excerpt":{"rendered":"<p>China\u2011based Jiangsu Hengrui Pharmaceuticals Co., Ltd. (HKG: 1276, SHA: 600276) announced that its two investigational&#8230;<\/p>\n","protected":false},"author":1,"featured_media":40086,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7,11],"tags":[62,2586,4228,852],"class_list":["post-40083","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-company","category-drug","tag-clinical-trial-approval-initiation","tag-hengrui-pharmaceuticals","tag-hkg-1276","tag-sha-600276"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v23.6 (Yoast SEO v27.5) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>Hengrui Pharmaceuticals Secures NMPA Approval for HRS\u20112162 and HRS\u20116093 Clinical Trials - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"China\u2011based Jiangsu Hengrui Pharmaceuticals Co., Ltd. (HKG: 1276, SHA: 600276) announced that its two investigational agents\u2014HRS\u20112162 and HRS\u20116093\u2014have received clearance from the National Medical Products Administration (NMPA) to enter clinical testing. The approval marks a significant step forward for the company\u2019s pipeline and positions Hengrui as a pioneer in two distinct therapeutic areas.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=40083\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Hengrui Pharmaceuticals Secures NMPA Approval for HRS\u20112162 and HRS\u20116093 Clinical Trials\" \/>\n<meta property=\"og:description\" content=\"China\u2011based Jiangsu Hengrui Pharmaceuticals Co., Ltd. (HKG: 1276, SHA: 600276) announced that its two investigational agents\u2014HRS\u20112162 and HRS\u20116093\u2014have received clearance from the National Medical Products Administration (NMPA) to enter clinical testing. The approval marks a significant step forward for the company\u2019s pipeline and positions Hengrui as a pioneer in two distinct therapeutic areas.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=40083\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2025-08-26T06:20:16+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2025-08-26T06:20:17+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2025\/08\/2608.webp\" \/>\n\t<meta property=\"og:image:width\" content=\"1080\" \/>\n\t<meta property=\"og:image:height\" content=\"608\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=40083#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=40083\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"Hengrui Pharmaceuticals Secures NMPA Approval for HRS\u20112162 and HRS\u20116093 Clinical Trials\",\"datePublished\":\"2025-08-26T06:20:16+00:00\",\"dateModified\":\"2025-08-26T06:20:17+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=40083\"},\"wordCount\":315,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=40083#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/08\\\/2608.webp\",\"keywords\":[\"Clinical trial approval \\\/ initiation\",\"Hengrui Pharmaceuticals\",\"HKG: 1276\",\"SHA: 600276\"],\"articleSection\":[\"Company\",\"Drug\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=40083#respond\"]}],\"copyrightYear\":\"2025\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=40083\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=40083\",\"name\":\"Hengrui Pharmaceuticals Secures NMPA Approval for HRS\u20112162 and HRS\u20116093 Clinical Trials - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=40083#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=40083#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/08\\\/2608.webp\",\"datePublished\":\"2025-08-26T06:20:16+00:00\",\"dateModified\":\"2025-08-26T06:20:17+00:00\",\"description\":\"China\u2011based Jiangsu Hengrui Pharmaceuticals Co., Ltd. (HKG: 1276, SHA: 600276) announced that its two investigational agents\u2014HRS\u20112162 and HRS\u20116093\u2014have received clearance from the National Medical Products Administration (NMPA) to enter clinical testing. The approval marks a significant step forward for the company\u2019s pipeline and positions Hengrui as a pioneer in two distinct therapeutic areas.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=40083#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=40083\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=40083#primaryimage\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/08\\\/2608.webp\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/08\\\/2608.webp\",\"width\":1080,\"height\":608,\"caption\":\"Hengrui Pharmaceuticals Secures NMPA Approval for HRS\u20112162 and HRS\u20116093 Clinical Trials\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=40083#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Hengrui Pharmaceuticals Secures NMPA Approval for HRS\u20112162 and HRS\u20116093 Clinical Trials\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Hengrui Pharmaceuticals Secures NMPA Approval for HRS\u20112162 and HRS\u20116093 Clinical Trials - Insight, China&#039;s Pharmaceutical Industry","description":"China\u2011based Jiangsu Hengrui Pharmaceuticals Co., Ltd. (HKG: 1276, SHA: 600276) announced that its two investigational agents\u2014HRS\u20112162 and HRS\u20116093\u2014have received clearance from the National Medical Products Administration (NMPA) to enter clinical testing. The approval marks a significant step forward for the company\u2019s pipeline and positions Hengrui as a pioneer in two distinct therapeutic areas.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=40083","og_locale":"en_US","og_type":"article","og_title":"Hengrui Pharmaceuticals Secures NMPA Approval for HRS\u20112162 and HRS\u20116093 Clinical Trials","og_description":"China\u2011based Jiangsu Hengrui Pharmaceuticals Co., Ltd. (HKG: 1276, SHA: 600276) announced that its two investigational agents\u2014HRS\u20112162 and HRS\u20116093\u2014have received clearance from the National Medical Products Administration (NMPA) to enter clinical testing. The approval marks a significant step forward for the company\u2019s pipeline and positions Hengrui as a pioneer in two distinct therapeutic areas.","og_url":"https:\/\/flcube.com\/?p=40083","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2025-08-26T06:20:16+00:00","article_modified_time":"2025-08-26T06:20:17+00:00","og_image":[{"width":1080,"height":608,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/08\/2608.webp","type":"image\/png"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=40083#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=40083"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"Hengrui Pharmaceuticals Secures NMPA Approval for HRS\u20112162 and HRS\u20116093 Clinical Trials","datePublished":"2025-08-26T06:20:16+00:00","dateModified":"2025-08-26T06:20:17+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=40083"},"wordCount":315,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"image":{"@id":"https:\/\/flcube.com\/?p=40083#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/08\/2608.webp","keywords":["Clinical trial approval \/ initiation","Hengrui Pharmaceuticals","HKG: 1276","SHA: 600276"],"articleSection":["Company","Drug"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=40083#respond"]}],"copyrightYear":"2025","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=40083","url":"https:\/\/flcube.com\/?p=40083","name":"Hengrui Pharmaceuticals Secures NMPA Approval for HRS\u20112162 and HRS\u20116093 Clinical Trials - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/flcube.com\/?p=40083#primaryimage"},"image":{"@id":"https:\/\/flcube.com\/?p=40083#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/08\/2608.webp","datePublished":"2025-08-26T06:20:16+00:00","dateModified":"2025-08-26T06:20:17+00:00","description":"China\u2011based Jiangsu Hengrui Pharmaceuticals Co., Ltd. (HKG: 1276, SHA: 600276) announced that its two investigational agents\u2014HRS\u20112162 and HRS\u20116093\u2014have received clearance from the National Medical Products Administration (NMPA) to enter clinical testing. The approval marks a significant step forward for the company\u2019s pipeline and positions Hengrui as a pioneer in two distinct therapeutic areas.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=40083#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=40083"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/?p=40083#primaryimage","url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/08\/2608.webp","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/08\/2608.webp","width":1080,"height":608,"caption":"Hengrui Pharmaceuticals Secures NMPA Approval for HRS\u20112162 and HRS\u20116093 Clinical Trials"},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=40083#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"Hengrui Pharmaceuticals Secures NMPA Approval for HRS\u20112162 and HRS\u20116093 Clinical Trials"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/08\/2608.webp","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/40083","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=40083"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/40083\/revisions"}],"predecessor-version":[{"id":40087,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/40083\/revisions\/40087"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/media\/40086"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=40083"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=40083"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=40083"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}